Registry for BRCA Mutation Carriers with Pancreatic Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to understand why certain individuals with a BRCA or PALB2 gene mutation develop pancreatic cancer. It involves creating a registry (a database) for carriers of these gene mutations who have pancreatic ductal adenocarcinoma, a common form of pancreatic cancer. Participants will provide blood specimens, answer a risk assessment questionnaire, and share tumor tissue samples if available. This trial suits those who know they carry a BRCA or PALB2 mutation, have or have had pancreatic cancer, or are related to someone with these mutations and pancreatic cancer. As an unphased trial, it offers a unique opportunity to contribute to groundbreaking research that could lead to better understanding and treatment options for pancreatic cancer.
Do I need to stop my current medications to join the trial?
The trial information does not specify whether you need to stop taking your current medications. It seems that both treated and untreated patients are eligible, so you may be able to continue your current treatments.
Why are researchers excited about this trial?
Researchers are excited about this trial because it aims to gather crucial data on BRCA mutation carriers with pancreatic ductal adenocarcinoma (PDAC) through blood specimens, risk assessment questionnaires, and tumor tissue samples. This registry may provide new insights into the genetic links between BRCA mutations and PDAC, potentially leading to earlier detection and more personalized treatment strategies. By understanding these connections, there’s hope for improved outcomes and more tailored care for individuals with this aggressive cancer.
Who Is on the Research Team?
David Kelsen, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Registry Establishment
Establishment of a BRCA mutation carriers PDAC Registry with appropriate control groups, and collection and storage of biological material for future studies
Follow-up
Participants are monitored for safety and effectiveness after registry establishment
What Are the Treatments Tested in This Trial?
Interventions
- Blood specimens
- The risk assessment questionnaire
- tumor tissue samples will be requested
How Is the Trial Designed?
5
Treatment groups
Experimental Treatment
who are not related to a BRCAmut PDAC patient
Who themselves have no known prior or active personal history of non-PDAC malignancy (e.g. breast , ovarian cancer or prostate cancer)
Patient who themselves have a known prior or active breast, ovarian cancer or prostate cancer
A family with at least two first or second degree relatives w ho have had PDAC.
who are proven non-BRCAmut carriers.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
Johns Hopkins University
Collaborator
Abramson Cancer Center of the University of Pennsylvania
Collaborator
Abramson Cancer Center at Penn Medicine
Collaborator
Shaare Zedek Medical Center
Collaborator
Sheba Medical Center
Collaborator
Dana-Farber Cancer Institute
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.